These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 16352712

  • 1. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
    Li M, Laco GS, Jaskolski M, Rozycki J, Alexandratos J, Wlodawer A, Gustchina A.
    Proc Natl Acad Sci U S A; 2005 Dec 20; 102(51):18332-7. PubMed ID: 16352712
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease.
    Satoh T, Li M, Nguyen JT, Kiso Y, Gustchina A, Wlodawer A.
    J Mol Biol; 2010 Aug 27; 401(4):626-41. PubMed ID: 20600105
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
    Tözsér J, Weber IT.
    Curr Pharm Des; 2007 Aug 27; 13(12):1285-94. PubMed ID: 17504236
    [Abstract] [Full Text] [Related]

  • 6. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
    Demir A, Oguariri RM, Magis A, Ostrov DA, Imamichi T, Dunn BM.
    Antivir Ther; 2012 Aug 27; 17(5):883-92. PubMed ID: 22436331
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
    Tözsér J, Zahuczky G, Bagossi P, Louis JM, Copeland TD, Oroszlan S, Harrison RW, Weber IT.
    Eur J Biochem; 2000 Oct 27; 267(20):6287-95. PubMed ID: 11012683
    [Abstract] [Full Text] [Related]

  • 8. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.
    Sperka T, Miklóssy G, Tie Y, Bagossi P, Zahuczky G, Boross P, Matúz K, Harrison RW, Weber IT, Tözsér J.
    J Gen Virol; 2007 Jul 27; 88(Pt 7):2052-2063. PubMed ID: 17554040
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
    Kádas J, Weber IT, Bagossi P, Miklóssy G, Boross P, Oroszlan S, Tözsér J.
    J Biol Chem; 2004 Jun 25; 279(26):27148-57. PubMed ID: 15102858
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Substrates and inhibitors of human T-cell leukemia virus type I protease.
    Ding YS, Rich DH, Ikeda RA.
    Biochemistry; 1998 Dec 15; 37(50):17514-8. PubMed ID: 9860866
    [Abstract] [Full Text] [Related]

  • 16. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
    Maegawa H, Kimura T, Arii Y, Matsui Y, Kasai S, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2004 Dec 06; 14(23):5925-9. PubMed ID: 15501070
    [Abstract] [Full Text] [Related]

  • 17. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM, Kimura T, Hidaka K, Kiso A, Nezami A, Freire E, Hayashi Y, Kiso Y.
    Biol Chem; 2004 Nov 06; 385(11):1035-9. PubMed ID: 15576323
    [Abstract] [Full Text] [Related]

  • 18. C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.
    Kádas J, Boross P, Weber IT, Bagossi P, Matúz K, Tözsér J.
    Biochem J; 2008 Dec 15; 416(3):357-64. PubMed ID: 18636969
    [Abstract] [Full Text] [Related]

  • 19. A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.
    Rücker P, Horn AH, Meiselbach H, Sticht H.
    J Mol Model; 2011 Oct 15; 17(10):2693-705. PubMed ID: 21279524
    [Abstract] [Full Text] [Related]

  • 20. Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease.
    Ma S, Vogt KA, Petrillo N, Ruhoff AJ.
    Comput Biol Chem; 2015 Jun 15; 56():61-70. PubMed ID: 25889320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.